Tysabri (natalizumab)-induced POU2AF1/Spi-B upregulation: STUDY

Image Source: TREATMERIGHTMS

High cumulative JC virus seroconversion rate during long-term use of Tysabri (natalizumab): STUDY

Image Source: IMAGEARCADE

Effect of Tysabri (natalizumab) on brain atrophy and disability progression in MS patients over 5 years: STUDY

Image Source: TREATMERIGHTMS

Re-evaluating the Incidence of Tysabri (Natalizumab)-Associated Progressive Multifocal Leukoencephalopathy: STUDY

Image Source: RYO1M

Disrupted balance of T cells under Tysabri (natalizumab) treatment in MS: STUDY

Image Source: THINKINGMACHINEBLOG

Disease-modifying treatments for MS – a review of approved medications: STUDY

Image Source: THEBRINLEYFAMILY

Monitoring the John Cunningham virus throughout Tysabri (natalizumab) treatment in MS patients: STUDY

HISTOLOGY: NERVOUS: BRAIN: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, PML; MULTINUCLEATED ASTROCYTE
Image Source: PEIRDIGITALLIBRARY

Natalizumab treatment reduces L-selectin (CD62L) in CD4 + T cells: STUDY

New MS Study Shows TYSABRI Improves Cognitive Impairment

Researchers at Spedali Civili of Brescia in Italy recently published findings in the journal PLoS One that Biogen’s Tysabri (natalizumab) can improve cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS) over the course of at least three years. The study is entitled “Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.”

Cognitive evolution in Tysabri treated Multiple Sclerosis patients: STUDY

Study tests safety & efficacy of new treatment intervals for MS therapy Tysabri (Natalizumab)

A new study presented last week during the American Academy of Neurology’s 67th Annual Meeting in Washington, DC provides new treatment strategies for multiple sclerosis (MS) using a monoclonal antibody already used in some MS patients.

A longitudinal study of cerebral gray matter volume in patients receiving Tysabri (natalizumab) for multiple sclerosis: STUDY

Improvement in Fatigue during Tysabri (Natalizumab) Treatment is Linked to Improvement in Depression and Day-Time Sleepiness

Increased relapse activity for multiple sclerosis Tysabri (natalizumab) users who become nonpersistent: a retrospective study: STUDY

Markers of JC virus infection in patients with multiple sclerosis under Tysabri (natalizumab) therapy

Second-Line Therapy with Gilenya (Fingolimod) for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Tysabri (Natalizumab): STUDY

Markers of JC virus infection in patients with multiple sclerosis under Tysabri (natalizumab) therapy: STUDY

Safety and Efficacy of Tysabri (Natalizumab) in Russian Participants With Relapsing Remitting Multiple Sclerosis: STUDY

Click here to read

Clinicians prescribing Tysabri/natalizumab for MS patients who are JC virus serum antibody–positive need to know about this progressive ataxia with cerebellar atrophy syndrome

Tysabri to Gilenya washout in patients at risk of PML: When good intentions yield bad outcomes.